Skip to main content

Table 4 Multivariate Cox regression analysis (in the subpopulation of Bev-treated patients)*

From: XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

 

Overall survival

Progression-free survival

HR

95% CI

Wald’s p

HR

95% CI

Wald’s p

Group

XELIRI-Bev

1

  

1

  

FOLFIRI-Bev

0.842

0.587–1.207

0.35

0.949

0.682–1.321

0.76

Performance status

0

1

  

1

  

1–2

1.710

1.164–2.513

0.006

1.375

0.952–1.986

0.090

Number of organs involved

1

1

  

1

  

2

1.580

1.052–2.373

0.027

1.475

1.019–2.135

0.040

≥3

2.598

1.502–4.493

0.001

2.305

1.337–3.973

0.003

Osteopontin (OPN)

Low

1

  

1

  

High

1.632

1.116–2.387

0.012

1.467

1.044–2.060

0.027

  1. *Both models remain the same whether continuous or binary variables of plasma concentrations of markers were used.
  2. HR, hazard ratio; CI, confidence interval.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us